093 Tumor mutational differences of cutaneous melanoma by age

Melanoma incidence and survival are age-dependent, with older patients having both higher rates worse outcomes. Here, we seek to examine age-dependent differences in mutational profiles of cutaneous melanoma, which may impact melanoma prognosis treatment-related Mutational 2263 were extracted from the American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange (v10.0) examined by age (< 30 years, 30-65 or > 65 years) tumor stage (primary metastatic). Mutation count distributions compared using Wilcoxon rank sum tests frequencies specific genes assessed Fisher’s exact test. Patients than years had significantly more mutations aged (Primary: P<0.05; Metastatic: P<0.001) younger P < 0.01; P<0.001). also less likely have BRAF (Metastatic: For metastatic tumors, DNA repair (P 0.001) 0.01). high burdens genes, influence immunotherapy BRAF, can be targeted vemurafenib. By identifying genomic age, our results provide insight into therapies most effective certain groups.